Skip to main content

Table 6 Active clinical trials involving nucleic acid-based therapies

From: Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence

NCT

Phase

Intervention

Target population

Location

Sample size

Key outcomes

NCT02766699

Phase I

Nanoparticles containing doxorubicin tied to bispecific antibodies (EGFR(V)-EDV-Dox) that are specific to the tumor cells of the patients

Recurrent glioblastoma

USA

20

Safety, MRI evaluation, recommended phase 2 dose, OS

NCT03491683

Phase I/II

INO-9012 (DNA plasmid for IL-12), INO-5401 (WT1 antigen, PSMA, hTERT genes) delivered via electroporation of cells, in combination with cemiplimab, with RT/TMZ

Newly diagnosed glioblastoma

USA

52

Adverse events, OS, change in T cell phenotypes

NCT03750071

Phase I/II

VXM01 (DNA plasmid vaccine for VEGFR-2) and avelumab (anti-PD-L1)

Recurrent glioblastoma

Germany

30

Adverse events, PFS, OS, MRI response, duration of response

NCT04485949

Phase IIb

IGV-001 (IGF-1R antisense oligonucleotide with autologous cell antigens) vs placebo with TMZ/RT

Newly diagnosed glioblastoma

USA

93

PFS, OS, MGMT status effect, functional changes, adverse events

NCT04573140

Phase I/II

Autologous tumor mRNA and pp65 LAMP mRNA-loaded liposomal vaccine

Newly diagnosed pediatric high-grade glioma and adult glioblastoma

USA

28

Production feasibility, safety, MTD